Elena Ridloff
Director/Board Member at KRONOS BIO, INC.
Net worth: 2 577 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nello Mainolfi | M | 45 | 9 years | |
| Felix Baker | M | 55 | 7 years | |
| Ellen Chiniara | F | 65 | 5 years | |
| Michael Cloonan | M | 53 |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Adam Rosenberg | M | 54 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Bruce Booth | M | 49 | 9 years | |
| Bruce Jacobs | M | 54 | 5 years | |
| Allison Frisbee | F | 41 | 4 years | |
| David Tanen | M | 52 | 7 years | |
| Tai Yin Yang | M | 70 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | 3 years |
| Arie Belldegrun | M | 74 | 7 years | |
| Joshua Kazam | M | 47 | 7 years | |
| Victor Sandor | M | 57 | 2 years | |
| Piyush Sharma | M | - | 7 years | |
| Brian Albarran | M | - | 6 years | |
| Brendan Teehan | M | 56 | 6 years | |
| Katherine Stultz | F | 50 | 1 years | |
| Elizabeth Garofalo | M | 66 | 4 years | |
| Mark Schneyer | M | 50 | 4 years | |
| Gorjan Hrustanovic | M | 35 | 4 years | |
| Roger Dansey | M | 67 | 1 years | |
| Roshawn Blunt | F | 49 | 3 years | |
| Norbert W. Bischofberger | M | 68 | 6 years | |
| Sandra Gardiner | F | 58 | 1 years | |
| Elizabeth A. Olek | M | 59 | 2 years | |
| Leigh Morgan | F | 56 | 2 years | |
| Joshua Resnick | M | 49 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Pamela Esposito | M | 50 | 4 years | |
| Matthew Kinsella | M | - |
Maverick Capital Ltd.
 Maverick Capital Ltd. Investment ManagersFinance Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors. | 19 years |
| Katherine Bishop | M | 58 | 3 years | |
| Paul Clancy | M | 62 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | 5 years |
| Joanna Horobin | M | 69 | 6 years | |
| Jeffrey Albers | M | 52 | 4 years | |
| Howard Marks | M | 77 |
University of Pennsylvania
| 24 years |
| John Maraganore | M | 60 | 2 years | |
| Juliet Williams | M | - | 3 years | |
| Charles Lin | M | 39 | 5 years | |
| Aimee Mishkin | F | - | 4 years | |
| Melissa Brody | F | - | 3 years | |
| Karen Weisbach | F | - | 3 years | |
| Raphael Amit | M | 77 |
University of Pennsylvania
| 25 years |
| Rocio Martin Hoyos | F | - | 3 years | |
| Jeremy Chadwick | M | 61 | 1 years | |
| Jared Gollob | M | 60 | 6 years | |
| James Kihara | M | - | 4 years | |
| Vijay Sabesan | M | 51 | 3 years | |
| Lucian Iancovici | M | 42 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Justine E. Koenigsberg | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Leonard Bell | M | 65 | 25 years | |
| David Brennan | M | 70 | 7 years | |
| Aradhana Sarin | M | 50 | 4 years | |
| Joseph A. Madri | M | 80 | 22 years | |
| David Hallal | M | 56 | 10 years | |
| Barbara Kosacz | F | 66 | 4 years | |
| Stephen P. Squinto | M | 67 | 23 years | |
| Kory Wentworth | M | 45 | 9 years | |
| Donald Nicholson | M | 67 | 5 years | |
| Stephanie Fagan | F | - | 2 years | |
| Nehal Kamalapat Chopra | F | - |
University of Pennsylvania
| 4 years |
| Jonathan Keehn | M | - |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors. | - |
| Rebecka Belldegrun | M | - | - | |
| César Orosco | M | - |
University of Pennsylvania
| 6 years |
| Tae Yamaura | F | - |
University of Pennsylvania
| 2 years |
| Sassan Alizadeh | M | - |
University of Pennsylvania
| 7 years |
| Susan Altschuller | M | 42 | 2 years | |
| John C. King | M | 49 | 9 years | |
| Jakob Loven | M | 46 | - | |
| Ludwig Hantson | M | 61 | 4 years | |
| Vijay Chattha | M | - |
University of Pennsylvania
| 5 years |
| Mark Day | M | 52 | 2 years | |
| Marianne de Backer | M | 55 | 2 years | |
| Rana Strellis | F | - | 4 years | |
| Robert Doebele | M | 53 |
University of Pennsylvania
| 4 years |
| Tina Beamon | F | - | 3 years | |
| Maja Sliwinski | F | - |
University of Pennsylvania
| 6 years |
| Yasir Al-Wakeel | M | 42 | 3 years | |
| Christopher Coughlin | M | 71 | 7 years | |
| Glenn F. Baity | M | 54 | 14 years | |
| Vijai P. Mohan | M | - |
University of Pennsylvania
| 5 years |
| Salvatore Tirabassi | M | - |
University of Pennsylvania
| 3 years |
| Francois Nader | M | 67 | 4 years | |
| Anne-Marie Law | F | 56 | 3 years | |
| Rockford Norby | M | 89 | 18 years | |
| John Martin | M | 72 | - | |
| Brian Kelly | M | 81 |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors. | - |
| M. Burns | F | 66 | 4 years | |
| Charles Hebard | M | - |
University of Pennsylvania
| 11 years |
| Paul Friedman | M | 81 | 4 years | |
| Doug Asiello | M | 54 |
University of Pennsylvania
| 3 years |
| David A. Cohen | M | - |
University of Pennsylvania
| 13 years |
| Max E. Link | M | 84 | 22 years | |
| James S. Riepe | M | - |
University of Pennsylvania
| 4 years |
| Erika G. Long | F | - |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors. | - |
| Saam Farhang | M | - |
University of Pennsylvania
| 5 years |
| Taran Sang Yong Bae | M | - |
University of Pennsylvania
| 2 years |
| Otello Stampacchia | M | 55 | 5 years | |
| Steve Hall | M | 69 | 5 years | |
| William Keller | M | 75 | 6 years | |
| Judith Reinsdorf | F | 60 | 3 years | |
| Karen Martin | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Elena Ridloff
- Personal Network
